Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SWI/SNF complex mutations promote thyroid tumor progression and resistance to redifferentiation therapy

ABSTRACT: SWI/SNF complex mutations promote thyroid tumor progression and resistance to redifferentiation therapy

PROVIDER: PRJNA614945 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11404800_1.fastq.gz	Fastqsanger.gz
	SRR11404800_2.fastq.gz	Fastqsanger.gz
	SRR11404801_1.fastq.gz	Fastqsanger.gz
	SRR11404801_2.fastq.gz	Fastqsanger.gz
	SRR11404802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 276

Similar Datasets

SWI/SNF complex mutations promote thyroid tumor progression and resistance to redifferentiation therapy [ATAC-seq]

Project description:Recurrent mutations in genes encoding subunits of the SWI/SNF chromatin remodeling complex occur commonly in human cancers of different lineages, including advanced thyroid cancers. Thyroid-specific loss of Arid1a, Arid2 or Smarcb1 in mouse BrafV600E-mutant tumors promotes disease progression and decreased survival, associated with lesion-specific effects on chromatin accessibility and differentiation. Swi/Snf loss leads to a repressive chromatin state at thyroid lineage transcription factors and their target binding sites, resulting in impaired expression of genes required for thyroid hormone biosynthesis. Thyroid differentiation and response to radioiodine therapy is restored by MAPK inhibitors in mouse BrafV600E-mutant thyroid cancers, which is abrogated in the context of Swi/Snf loss. MAPK inhibitors also failed to restore thyroid differentiation and radioiodide incorporation in patients with BRAFV600E or RAS-mutant tumors with SWI/SNF mutations. SWI/SNF complexes are central to the maintenance of differentiated thyroid function, and their loss confers RAI refractoriness and resistance to MAPK inhibitor-based redifferentiation therapies.

2020-12-02 | GSE162522 | GEO